

15<sup>th</sup> May 2026

## Vitasora Executes vCare Rollout as Revenue Scaling Accelerates

### Highlights

- vCare EMR platform successfully implemented from 1 April 2026, delivering on milestones outlined in the March Quarterly Report
- RPM module completed and expected to launch from 1 July 2026, enabling full transition from Ceras while maintaining CMS reimbursement integrity
- vCare platform transition expected to reduce SaaS costs by >90% and deliver ~US\$1.7M in annualised operating savings.
- Approximately 40,000 existing client patient opportunity now entering accelerated enrolment phase
- April enrolments reached 469 patients, almost double February and March monthly averages
- May Month-to-Date enrolments imply monthly run-rate exceeding 550 patients, representing growth of more than 130% versus February/March
- Every additional 1,000 engaged patients is expected to generate approximately US\$70,000–US\$120,000 in monthly revenue
- ~US\$490k collected post quarter-end from 31 March receivables, with 60+ day debtors reduced by ~30% and 90+ day debtors reduced by ~40%
- The Company continues to progress toward targeted monthly business-as-usual cashflow breakeven, expected in H2 CY2026

Vitasora Health Limited (ASX: VHL; OTCQB: VHLUF) (“Vitasora” or “the Company”) a leader in AI-powered connected care and chronic disease management solutions, is pleased to provide an operational update following the successful execution of key initiatives outlined in its March 2026 Quarterly Activities Report.

The Company confirms that the implementation of its proprietary vCare Electronic Medical Record (EMR) platform was successfully executed from 1 April 2026 and is now operational across the Chronic Care Management (CCM) business.

Importantly, the rollout has progressed in line with management expectations and has enabled the Company to transition patient operations and workflows onto a unified and scalable operating platform designed to improve enrolment efficiency, workforce flexibility, patient engagement, and reimbursement integrity.

The RPM module within vCare has now been completed and is currently undergoing final live operational testing. Subject to completion of final validation processes, the Company expects the RPM module to launch from 1 July 2026 to align with full client reimbursement cycles and mitigate data risk.

This milestone is expected to enable a complete operational transition from the legacy Ceras platform onto vCare, supporting improved workflow efficiency, data integrity and continuity of CMS reimbursement capture for clients and patients.

From July 2026, Vitasora expects to realise the full financial benefits of its transition to the proprietary vCare platform, reducing software platform costs by more than 90%, from approximately US\$7 to less than US\$1 per patient per month.

For every 10,000 active patients, this reduction alone is expected to generate annualised SaaS savings of

approximately US\$720K (A\$1.05M).

Combined with a further ~US\$1M in annualised operating efficiencies from workflow automation, improved workforce utilisation and reduced reliance on third-party platforms, the Company expects total annualised savings of approximately US\$1.7–1.8M (AUD\$2.4-2.6M).

These initiatives are expected to materially enhance operating leverage and accelerate Vitasora's pathway to business-as-usual cashflow breakeven.

The Company also advises that the previously disclosed ~40,000 patient opportunity from existing clients is now entering an active enrolment acceleration phase.

Following a deliberately moderated enrolment period, during the March quarter, to facilitate platform optimisation and workflow refinement, enrolment activity has increased materially since implementation of vCare.

April 2026 patient enrolments totalled 469 patients, representing almost double the average monthly enrolments achieved during February and March 2026.

Momentum has continued into May, with 163 patient enrolments completed within the first seven billing days of the month. Based on current trends, this represents an implied monthly run-rate exceeding 550 enrolments, or growth of more than 130% compared to February/March 2026.

The Company estimates that each additional 1,000 active patients enrolled into Vitasora programs may generate approximately US\$70,000–US\$120,000 in monthly revenue depending on care mix and reimbursement pathways.

At an average Fee-for-Service revenue of approximately US\$85 per patient per month, the Company estimates that approximately 6,500 billed Fee-for-Service patients would support monthly Fee-for-Service revenue of approximately US\$550K. Combined with existing UPEC (Call Centre services) and TCM/PMPM revenue streams, this would represent an estimated monthly revenue run-rate of approximately US\$650K which is the forecast business-as-usual profitability threshold.

The Company's current billed Fee-for-Service patient base is approximately 2,800 patients. Based on current enrolment momentum, operational efficiencies and RPM expansion opportunities, management remains focused on progressing toward targeted monthly business-as-usual monthly profitability in H2 CY2026.

Marjan Mikel, CEO of Vitasora, said:

“The successful implementation of vCare marks a transformational milestone for Vitasora. Importantly, we have now executed on the operational initiatives outlined in our March Quarterly update and are already seeing tangible acceleration in patient onboarding activity.

The completion of the RPM module positions us to fully transition from legacy systems while maintaining reimbursement integrity and continuity for our clients. Early enrolment trends are encouraging and reinforce management's confidence in the scalability of the platform, the strength of demand from our existing client base and our pathway toward sustainable operational cashflow generation.”

Further, the Company has made strong progress improving cash collections and debtor ageing, subsequent to quarter end. Of the US\$990k accounts receivable balance at 31 March, approximately US\$490k has already been collected as at mid-May. Importantly, 60+ day receivables have reduced by approximately 30% and 90+ day receivables by approximately 40% versus the March ageing profile, reflecting improved cash conversion,

stronger collection performance, and increasing operational discipline across the business. Based on ongoing customer engagement, the Company remains confident in the recoverability of the remaining receivables, noting that timing of collections may vary.

## Outlook

The Company remains focused on accelerating patient enrolment across its existing contracted client base and improving patient engagement, reimbursement capture, and operational efficiency as vCare moves into full deployment.

Further updates will be provided as enrolment acceleration progresses and the RPM module moves into commercial launch from July 2026.

This announcement has been authorised for release by the Board of Directors of Vitasora Health Limited.

For further information, investors and media please contact:

**Mr Marjan Mikel**

CEO & Managing Director

Vitasora Health Limited

P: +61 408 462 873

E: [marjan@vitasorahealth.com](mailto:marjan@vitasorahealth.com)

**Mr Nicholas Smedley**

Non-Executive Chairman

Vitasora Health Limited

P: +61 447 074 160

E: [nicholas@vitasorahealth.com](mailto:nicholas@vitasorahealth.com)

### About Vitasora Health Limited – A Revolutionary Remote Healthcare Solutions Provider

Vitasora Health Limited (ASX:VHL, OTCQB:VHLUF) is redefining digital Connected Care in the U.S. healthcare market. We combine cutting-edge technologies and expert clinical teams to deliver a turnkey solution for providers. Our remote patient monitoring (RPM) and chronic care management (CCM) services improve outcomes, reduce costs, and help healthcare clients thrive in a value-based world. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We are revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Connected Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at [www.vitasorahealth.com.au](http://www.vitasorahealth.com.au)

### About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Vitasora, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respiri.co/us/> or for [wheezo.com](http://wheezo.com)

Vitasora Health Limited is headquartered in Melbourne with offices in Los Angeles.

wheezo® is a registered trademark of Vitasora Health Limited